This phase 2 trial tests whether adding the targeted drug alpelisib to ongoing hormone therapy can help people with a specific genetic mutation (PIK3CA) in advanced breast cancer that has stopped responding to hormone therapy alone. About 44 participants will take daily alpelisib…
Phase: PHASE2 • Sponsor: Marina N Sharifi • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC